Keep Up with the Latest Clinical Updates
Clinical and scientific leaders from around the country provide their views on the latest clinical data regarding head lice therapy and management.
Head Lice Resistance
Leading head lice expert, Dr. J Marshall Clark, offers his perspectives on how known resistance has rendered OTCs ineffective.
Impact on Mental Health
Dr. Shirley Gordon, Director of the Head Lice Treatment and Prevention Project, talks about the negative impact head lice can have on mental health.
Download the companion white paperA concept analysis demonstrating how stigmas result from head lice infestations is also available from Dr. Sheila Hurst, Assistant Professor of ADN Nursing at North Idaho College.
Download the articleEvidence-Based Clinical Data
According to Dr. Christopher Belcher, MD, FAAP, all the latest clinical data points to Spinosad Topical Suspension 0.9% as the standard of care for head lice treatment.1,2
Download the companion white paperPrimary Studies and Systematic Review Articles
Gellatly KJ, Krim S, Palenchar DJ, et al. Expansion of the Knockdown Resistance Frequency Map for Human Head Lice (Phthiraptera: Pediculidae) in the United States Using Quantitative Sequencing. J Med Entomol. 2016;53(3):653-659.
Download the articleYoon KS, Clark JM, et al. Knockdown Resistance Allele Frequencies in North American Head Louse (Anoplura: Pediculidae) Populations. Med Entomol. 2014;51(2):450-457.
Download the articleHodgdon HE, Yoon KS, Previte DG, et al. Determination of knockdown resistance allele frequencies in global head louse populations using the serial invasive signal amplification reaction. Pest Manag Sci. 2010;66(9):1031-1040.
Download the articleYoon KS, Gao JR, Lee SH, Clark JM, Brown L, Taplin D. Permethrin-resistant human head lice, Pediculus capitis, and their treatment. Archives of Dermatology. 2003;139(8):994-1000.
Download the articleReference(s)
- IQVIA: June 11, 2021.
- Spinosad Topical Suspension 0.9% Prescribing Information.
SPN-RRW3-002